Navigation Links
Drugstore of the future -- new drugs from an old source
Date:11/10/2010

Toronto, ON (Nov. 10 2010) Supported by thousands of years of use, a new wave of polymolecular botanical drugs (PBDs), backed by strong biomedical research and clinical trials, are growing in acceptance as a viable new drug category for the treatment and prevention of a wide spectrum of diseases from cancer to obesity.

Leading researchers in drug development from the National Cancer Institute, Wake Forest University, the University of California, the Scripps Centre for Integrative Medicine, King's College in London UK, and many Canadian Universities will be among the twenty panellists at a Toronto forum on November 15th. Speakers will highlight recent discoveries, discuss current and future research, and chart regulatory landscapes for the promising field of polymolecular drug development. Treatment areas include diabetes, cholesterol management, and cancer.

Research findings will be presented illustrating the advances in the development of polymolecular drugs and their growing recognition as potential mainstream therapies to not only treat illness, but to prevent it. Since polymolecular drugs are composed of multiple components, they often produce biological and/or clinical efficacy through multiple mechanisms of action rather than through a single pathway, as conventional drugs do. An added advantage of this new class of drugs is the synergy between their components, which allows for lower concentrations of each individual ingredient with no reduction in efficacy. As a result they are, as a category, safer and more tolerable than conventional drugs.

Discussion will also focus on recent successes in standardization, which overcome the greatest challenge of botanical medicine and allow for assurances of consistency, safety, and efficacy.

The list of speakers at the forum will include:

  • Dr. Erminia Guarneri, founder and medical director of the Scripps Center for Integrative Medicine, who will deliver the keynote address, titled Personalized, Predictive, Pro-Active Health: Treating the Whole Person, Body, Mind & Spirit
  • Dr. Pierre Haddad, Professor at the University of Montreal presenting on novel anti-obesity and anti-diabetic properties of plants originating from the Boreal forest of Canada.
  • Dr. Peter Hyland: Professor, King's College, UK, presenting on novel standardization methods for polymolecular drugs.
  • Dr. Auro del Giallo, ABC Foundation School of Medicine, San Paulo Brazil presenting on polymolecular drugs and their role in treating cancer related fatigue
  • Dr. Jeffrey White, MD, Director, Office of Cancer Complementary and Alternative Medicine, National Cancer Institute, NIH, DHHS presenting on the US National Cancer Institute and its botanical research

Academic and clinical researchers, business development professionals and government agencies involved in the drug development field have been invited to attend and learn about this emerging field of health and therapeutics, and to network with other professionals in the field.


'/>"/>

Contact: Dr. Bhagirath Singh
bhagi.singh@schulich.uwo.ca
416-644-2287
CV Technologies Inc.
Source:Eurekalert

Related biology news :

1. An underwater drugstore?
2. Putting a bulls-eye on the flu: Paper details influenzas structure for future drug targeting
3. Shaping the future of the High Plains water supply
4. For future chips, smaller must also be better
5. ‘Scientific leaders of the future’ gear up for important talks on Capitol Hill
6. Lead-free piezoelectric materials of the future
7. Louisiana Tech forestry professor helps to shape future of global industry research
8. Glorious gadolinium gives flash memory a future
9. A future with or without trees
10. Unaccounted feedbacks from climate-induced ecosystem changes may increase future climate warming
11. Food for our future -- its more than whats for dinner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... 10, 2017 Research and Markets ... "Personalized Medicine - Scientific and Commercial Aspects" to their ... ... is integrated with therapy for selection of treatment as well ... and prevention of disease in modern medicine. Biochip/microarray technologies and ...
(Date:2/8/2017)... 2017 The biometrics market has reached ... of organizations, desires to better authenticate or identify ... and challenge questions), biometrics is quickly working its ... market is driven by use cases, though there ... enterprise uses cases, with consumer-facing use cases encompassing ...
(Date:2/6/2017)... DENVER , Feb. 6, 2017 ... national security are driving border authorities to continue ... Acuity reports there are 2143 Automated Border Control ... Kiosks currently deployed at more than 163 ports ... between 2013 to 2016 achieving a combined CAGR ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... SAN DIEGO , Feb. 22, 2017 ... announced today expansion of its translational research program ... through establishment of laboratory facilities in San Diego.  ... San Diego BioLabs facility, a biotechnology incubator sponsored ... Sanofi. In November 2016, the Company ...
(Date:2/21/2017)... , Feb. 21, 2017 Synthetic Biologics, Inc. ... to preserve the microbiome to protect and restore the health of ... year ended December 31, 2016 on Thursday, March 2, 2017, and ... EST. The dial-in information for the call is as follows: ... ...
(Date:2/21/2017)... ... February 21, 2017 , ... During HIMSS ... digital health applications, announced a partnership with Redox, a leader in cloud-based healthcare ... many clinical systems while keeping data secure in the cloud. , The digital ...
(Date:2/21/2017)... ... February 21, 2017 , ... Genedata, a leading provider of ... the establishment of Genedata Limited as a new subsidiary in the United Kingdom. ... life science informatics. Creating the UK subsidiary reinforces Genedata’s commitment to collaborate closely ...
Breaking Biology Technology: